Syndax Pharmaceuticals
SNDX
142 hedge funds and large institutions have $1.03B invested in Syndax Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 50 increasing their positions, 24 reducing their positions, and 11 closing their positions.
400% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 11
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
144% more call options, than puts
Call options by funds: $8.49M | Put options by funds: $3.48M
108% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 24
105% more capital invested
Capital invested by funds: $505M → $1.03B (+$530M)
43% more funds holding
Funds holding: 99 → 142 (+43)
11.63% more ownership
Funds ownership: 88.81% → 100.43% (+12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$32.1M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$30.2M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$25.9M |
| 4 |
HM
HealthCor Management
New York
|
+$21.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$33M |
| 2 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$27.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$14.8M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$6.9M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.51M |
SNDX Hedge Fund Activity: Q4 2020 in Review
142 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2020, worth a combined $1.03B — up 105% from $505M a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new SNDX positions and 11 closed out — a net gain of 44 holders — while 50 added to existing stakes and 24 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $32.1M. The largest seller was BVF Inc, cutting an estimated $33M.
- 142 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2020, up from 99 in Q3 2020.
- Funds reported $1.03B of Syndax Pharmaceuticals stock for Q4 2020, up 105% quarter-over-quarter.
- 55 funds opened new Syndax Pharmaceuticals positions in Q4 2020 and 11 closed out, a net change of +44 holders.
- The largest Syndax Pharmaceuticals buyer in Q4 2020 was Citadel Advisors, an estimated $32.1M added.
- The largest Syndax Pharmaceuticals seller in Q4 2020 was BVF Inc, an estimated $33M sold.
Based on aggregated 13F filings for Q4 2020.